Searchable abstracts of presentations at key conferences in endocrinology

ea0015p117 | Diabetes, metabolism and cardiovascular | SFEBES2008

Glucagon-like peptide-1 responses following multiple meals in lean and obese subjects

Ahweyevu Rukevwe , Bhogal Randip , Le Roux Carel

Background: Food intake and body weight are in a constant sense of balance, which is tightly regulated. The central control of appetite by the hypothalamus and areas in the brainstem has been established. The peripheral regulation of appetite via gut hormones has also been alluded to – previous studies have shown PYY and ghrelin hormones to be altered in obesity. Glucagon-like peptide-1 is a gut hormone released from L-cells in the distal ileum and colon. It has been impl...

ea0021p45 | Clinical practice/governance and case reports | SFEBES2009

Bariatric surgery in renal transplant recipients

Kamaledeen Salma S , Bueter Marco , Ahmed Ahmed , Le Roux Carel W

Objectives: The long-term outcome of bariatric surgery on renal function in the morbidly obese renal transplant recipient is still unknown. We describe three cases of morbidly obese renal transplant recipients who have subsequently undergone bariatric surgery.Patient 1: A 44-year-old man (BMI 42.2 kg/m2) had received a renal transplant for chronic renal disease secondary to childhood reflux nephropathy. Laparoscopic Roux-en-Y gastric bypass re...

ea0021p134 | Diabetes and metabolism | SFEBES2009

Bariatric surgery in renal transplant recipients

Kamaledeen Salma S , Bueter Marco , Ahmed Ahmed , Le Roux Carel W

Objectives: The long-term outcome of bariatric surgery on renal function in the morbidly obese renal transplant recipient is still unknown. We describe three cases of morbidly obese renal transplant recipients who have subsequently undergone bariatric surgery.Patient 1: A 44-year-old man (BMI 42.2 kg/m2) had received a renal transplant for chronic renal disease secondary to childhood reflux nephropathy. Laparoscopic Roux-en-Y gastric bypass re...

ea0048p1 | Poster Presentations | SFEEU2017

Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial

McGowan Barbara , Fujioka Ken , Greenway Frank , Krempf Michel , Le Roux Carel , Vettor Roberto , Lilleore Soren , Astrup Arne

Aims/objectives: Obesity and prediabetes are risk factors for developing T2D. 5–10% weight-loss can reduce risk of developing T2D by >50%. The 3-year part of this phase 3 trial investigated effects of liraglutide 3.0 mg, as adjunct to diet+exercise, in delaying onset of T2D over 3 years, body-weight and cardiometabolic risk factors in adults with obesity or overweight with comorbidities, and diagnosed with prediabetes at screening.Methods: Indiv...

ea0037ep515 | Diabetes (complications & therapy) | ECE2015

Roux-en-Y gastric bypass reduces proteinuria in diabetic kidney disease to a greater extent than weight loss alone in the Zucker diabetic fatty rat without a greater improvement in renal inflammation

Neff Karl , Elliott Jessie , Jackson Sabrina , Abegg Kathrin , Corteville Caroline , Munoz Rodrigo , Docherty Neil , Lutz Thomas , le Roux Carel

Background: The effect of Roux-en-Y gastric bypass (RYGB) on diabetic kidney disease (DKD) is unclear. We used a Zucker diabetic fatty rat (ZDF) model of DKD to determine the effect of RYGB on histopathological markers of DKD, proteinuria, and MCP1 excretion.Methods: ZDF rats underwent RYGB (n=15) or sham surgery (n=14) at 18 weeks of age. Eight sham operated animals were food restricted to match the weight loss of the RYGB group (body-...

ea0021p128 | Cytokines and growth factors | SFEBES2009

Blood pressure, renal cytokines and biochemical parameters improve in morbidly obese patients after bariatric surgery

Dubb Sukhpreet Singh , Bueter Marco , Gill Abhijit , Ahmed Ahmed R , Frankel Andrew , Le Roux Carel W , Tam Frederick

Introduction: Obesity related glomerulopathy (ORG) is an emerging epidemic alongside increasing incidences of obesity. ORG pathophysiology has not been explored despite poor prognosis in untreated patients. MCP-1, MIF, CCL-18 and CCL-15 are novel cytokines that may be pathologically involved in obesity-induced renal injury and explored in this study.Methods: Blood pressure, urine and blood samples were collected from 34 morbidly obese patients before and...

ea0019p281 | Reproduction | SFEBES2009

Effect of rimonabant and metformin on GIP and GLP-1 in obese women with polycystic ovary syndrome

Sathypalan Thozhukat , Cho LiWei , Kilpatrick Eric S , Le Roux Carel W , Coady Anne-Marie , Atkin Stephen L

Objective: Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with PCOS compared to metformin. Metformin has also been shown to maintain the weight loss and enhance the metabolic and biochemical parameters achieved by treatment with rimonabant. We have determined the effect of rimonabant on the incretin hormones in patients with PCOS.Design: A randomized open labelled parallel study of metformin...

ea0094p351 | Metabolism, Obesity and Diabetes | SFEBES2023

Time-restricted eating in polycystic ovarian syndrome: a randomised crossover feasibility study of real-world clinical advice

Floyd Ruairi , Gibney James , Owens Lisa , Phelan Niamh , Rakovac Ana , Le Roux Carel , Duggan Sinead , Ann Behan Lucy

Objective: Time-restricted eating (TRE) represents a novel intervention that may improve insulinaemia and reduce weight, but is untested in polycystic ovarian syndrome (PCOS). In a randomised interventional study (NCT05126199), we investigated the feasibility of TRE in PCOS. Secondary objectives included effects on insulin and metabolic indices.Methods: Participants were randomised to 12-week TRE (18h fast/6h eating wind...

ea0077op4.2 | Metabolism, Obesity and Diabetes | SFEBES2021

3 mg Liraglutide ameliorates inflammation and improves hypothalamic regulation of energy homeostasis by modulation of Sphingosine-1-Phosphate signalling in super-responders

Spencer Lewis , Dimitriadis Georgios K , Duggirala Aparna , Bate Danielle , Davasgaium Allan , Al-Hasani Wiaam , D Miras Alexander , Le Roux Carel , Vincent Royce P , Randeva Harpal S , Tripathi Gyanendra

Background: Growing evidence suggests that hypothalamic lipid sensing plays a key role in controlling food intake, fat deposition and energy balance and that its dysregulation could lead to obesity and type 2 diabetes (T2D). Recent investigations reported that sphingosine-1-phosphate (S1P) is involved in the hypothalamic control of energy homeostasis. Intra-cerebroventricular administration of S1P decreased food intake and increased energy expenditure in rodents.<p class="...